Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Cancer Res. 2011 Apr 4;71(11):3963–3971. doi: 10.1158/0008-5472.CAN-10-0906

Figure 2. Seven-day CED of topotecan causes loss of identifiable tumor cells.

Figure 2

A. PDGF retroviral tumor after 7-day CED of PBS. Note the large proliferative lesion with cells invading through the corpus callosum (CC). Thick arrow points to the injection/cannula site. Thin arrows point to areas of pseudopalisading necrosis. B. Topotecan-treated brain (7 days post-treatment) shows the absence of any identifiable tumor cells.